论文部分内容阅读
为了研究唾液酸在恶性肿瘤患者中的含量变化以及评价疗效，监测转移、复发和预后，采用单步显色比色法检测了94例确诊恶性肿瘤患者和470例健康人血清总唾液酸（TSA）水平，同时也检测了其中60例患者和另外135例健康人血清脂质结合唾液酸（LSA）水平。结果发现：健康对照组血清TSA和LSA平均水平为（1．47±0.29）mmol／L和（0．34±0．11）mmol／L，恶性肿瘤患者平均水平分别为（2．21±0.56）mmol／L和（0.57±0.62）mmol／L，后者明显高于前者（P＜0．01）；病理组织学分型鳞癌和混合癌的LSA高于腺癌（P＞0．05和P＜0.05），治疗后归转为病情稳定或好转者，TSA明显下降（P＜0.001），恶化或死亡者，TSA和LSA均无降低。初步认为：SA可作为一种恶性肿瘤标记物之一，同时也可能作为癌患者疗效评价、预测转移、复发和判断预后的一种有用的指标。
In order to study the changes of the content of sialic acid in patients with malignant tumors and evaluate the efficacy, and to monitor metastasis, recurrence, and prognosis, 94 patients diagnosed with malignant tumors and 470 healthy individuals were tested for total sialic acid (TSA) by single-step colorimetric assay. Serum levels of lipid-associated sialic acid (LSA) were also measured in 60 patients and 135 healthy individuals. The results showed that the average levels of serum TSA and LSA in healthy controls were (1.47±0.29) mmol/L and (0.34±0.11) mmol/L, and the average levels of malignant tumors were (2.21±0.56). )mmol/L and (0.57±0.62) mmol/L, the latter was significantly higher than the former (P<0.01); the histopathological type squamous cell carcinoma and mixed carcinoma had higher LSA than adenocarcinoma (P>0.05 and P<0.05). After treatment, the condition was stable or improved, TSA decreased significantly (P<0.001), deterioration or death, TSA and LSA did not decrease. It is initially thought that SA can be used as one of the markers of malignant tumors, and it may also serve as a useful indicator for evaluating the efficacy, predicting metastasis, recurrence, and prognosis of cancer patients.